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Abstract
Background: Understanding the environmental and genetic risk factors of accelerated lung function decline in
the general population is a first step in a prevention strategy against the worldwide increasing respiratory
pathology of chronic obstructive pulmonary disease (COPD). Deficiency in antioxidative and detoxifying
Glutathione S-transferase (GST) gene has been associated with poorer lung function in children, smokers and
patients with respiratory diseases. In the present study, we assessed whether low activity variants in GST genes
are also associated with accelerated lung function decline in the general adult population.
Methods: We examined with multiple regression analysis the association of polymorphisms in GSTM1, GSTT1
and GSTP1 genes with annual decline in FEV1, FVC, and FEF25–75 during 11 years of follow-up in 4686 subjects of
the prospective SAPALDIA cohort representative of the Swiss general population. Effect modification by smoking,
gender, bronchial hyperresponisveness and age was studied.
Results: The associations of GST genotypes with FEV1, FVC, and FEF25–75 were comparable in direction, but most
consistent for FEV1. GSTT1 homozygous gene deletion alone or in combination with GSTM1 homozygous gene
deletion was associated with excess decline in FEV1 in men, but not women, irrespective of smoking status. The
additional mean annual decline in FEV1 in men with GSTT1 and concurrent GSTM1 gene deletion was -8.3 ml/yr
(95% confidence interval: -12.6 to -3.9) relative to men without these gene deletions. The GSTT1 effect on the
FEV1 decline comparable to the observed difference in FEV1 decline between never and persistent smoking men.
Effect modification by gender was statistically significant.
Conclusion:  Our results suggest that genetic GSTT1  deficiency is a prevalent and strong determinant of
accelerated lung function decline in the male general population.
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Background
According to estimates by the World Health Organization
chronic obstructive pulmonary disease (COPD) has
become the fourth most common single cause of death
and its prevalence is further increasing world wide [1].
COPD is characterized by irreversible and progressive
bronchial obstruction and is associated with persistent
airway inflammation [2]. Excess age-related lung function
decline is considered a subclinical correlate of COPD and
is associated with morbidity and premature mortality [3].
The identification of risk factors leading to accelerated
lung function decline is thus needed for efficient COPD
prevention. Modifiable risk factors for COPD include
active cigarette smoking, occupational dust and fume
exposure [4] and possibly air pollution [5] and passive
smoking [6].
But there is also broad evidence that genetic differences
influence the individual's susceptibility to COPD. Rare
mutations in the SERPINA1 gene [7], leading to severe
alpha 1-antitrypsin deficiency, in the SERPINE2, protease
inhibitor 7 gene, and in the ELN, elastin gene, have been
identified as genetic predisposing factor in families with
early onset COPD [8,9]. To what degree common genetic
variants influence susceptibility to COPD in the general
population is the focus of intensive research efforts. There
is limited evidence from association studies on common
genetic polymorphisms in various candidate genes that
modify the individual's risk for lung function deficits and
COPD [10-13]. But several lines of evidence point to the
involvement of the supergene family of glutathione S-
transferase (GST) in respiratory disease etiology, includ-
ing that of COPD. Given their function in the metabolism
of environmental toxicants as well as in the inactivation of
reactive oxygen species, these genes represent promising
candidates for modification of the susceptibility to
tobacco-smoke derived and other inhaled irritants
[14,15]. Two prevalent homozygous gene deletions of the
Mu-1 and Theta-1 GST members (GSTM1  and GSTT1)
have repeatedly been associated with increased suscepti-
bility to respiratory disease and lung function deficits in
children, asthmatics, and smokers with respiratory symp-
toms [16-20]. It is, however, unknown whether these GST
polymorphisms also influence lung function in the gen-
eral population. We therefore investigated the association
of the three most studied GST polymorphisms (GSTM1
and GSTT1 gene deletions and GSTP1 Ile105Val single
nucleotide polymorphism) with change in lung function
over an eleven year follow-up using the population-based
SAPALDIA cohort (Swiss Cohort Study on Air Pollutants
and Lung and Heart Diseases in Adults) and hypothesized
that low-activity variants would also accelerate lung func-
tion decline in the general adult population.
Methods
Study population
The SAPALDIA cohort study has been described in details
elsewhere [21,22]. In brief, participants predominantly of
European-Caucasian ethnicity and Swiss nationality, were
randomly selected from eight regional population regis-
tries [21,22]. Health examinations at baseline (1991) and
follow-up (2002) included an interview about respiratory
health, occupational and lifestyle exposures as well as
spirometry, a methacholine bronchial challenge test and
end-expiratory carbon monoxide measurement. Partici-
pants gave informed consent at both surveys separately for
health examination, interview and blood analysis. The
SAPALDIA cohort study complies with the Helsinki Dec-
laration and has received ethical approval by the central
ethics committee of the Swiss Academy of Medical Sci-
ences and the Cantonal Ethics Committees for each of the
eight examination areas.
Participation rate in SAPALDIA at baseline was 59.3%. Of
9651 participants examined at baseline, 8047 subjects
(86%) agreed to participate fully or partially at follow-up.
For the present investigation no selection of SAPALDIA
participants was made, but we included all subjects with
complete information on outcome and covariate data.
5973 subjects (62%) completed the entire follow-up pro-
tocol including spirometry and blood sampling. For 275
participants no DNA was available for genetic testing due
to refusal or insufficient blood sample volume. Valid
spirometry data on FEV1, FVC and FEF25-75 were not avail-
able from both surveys for 215, 310 and 373 participants,
respectively. Genotyping for one or more genetic poly-
morphisms failed in 13 participants. Missing information
on one or more covariates included in the regression
models further diminished the sample size (n = 784). The
final sample size was 4686, 4591 and 4528 subjects for
the investigation of annual change in FEV1, FVC and
FEF25-75, respectively. Comparison of the baseline charac-
teristics of SAPALDIA cohort participants included in and
excluded from this analysis revealed that excluded SAPA-
LDIA participants were on average older, more likely to
have been smokers at baseline examination, and had
reported a slightly higher number of pack-years at base-
line (Table 1). Accordingly lung function was slightly
lower and the proportion of subjects with an FEV1/FVC
ratio below 70% was slightly higher in non-participants
excluded from this current investigation.
INSERT [Table 1]
Spirometry and bronchial hyperresponsiveness
The spirometry measurement procedures at both time
points have been described elsewhere in detail [21,22].
Briefly, identical spirometer devices (Sensormedics model
2200, Yorba Linda, USA) and protocols were used at base-Respiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
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line and follow-up and their comparability was assessed
prior to the follow-up study [23]. Three to maximal eight
forced expiratory lung function manoeuvres were per-
formed by each participant and a minimum of two accept-
able forced expiratory flows, forced vital capacity (FVC),
forced expiratory volume in the first second (FEV1) and
forced expiratory flows during the middle half of the FVC
(FEF25–75) complying with American Thoracic Society cri-
teria [24] were obtained. Expiratory flow measures with
the highest sum of FVC, FEV1 and FEF25–75 were taken
from the same flow-volume curves.
Bronchial hyperresponsiveness (BHR) to methacholine
chloride (Provocholine®, Roche, Nutley, New Jersey, USA)
was defined as presence of a 20% or greater drop in FEV1
compared to the highest FEV1-value measured during the
test. Increasing concentrations of methacholine (0.39,
1.56, 6.25, and 25.0 mg/ml solutions in a phosphate
buffer without phenol) were administered through an aer-
osol dosimeter (Mefar MB3, Bovezzo, Italy) up to a cumu-
lative dose of 2 mg (8.37 ug/mol).
Genotyping
DNA was extracted from EDTA blood using the PURE-
GENE™ DNA purification kit (GENTRA Systems, Minne-
apolis, USA)[21]. In all subjects GSTM1 and GSTT1 gene
deletions and a single nucleotide polymorphism (SNP) in
GSTP1 leading to the amino acid substitution Ile105Val
were genotyped on the ABI Prism 7000 sequence detec-
tion system (Applied Biosystems, Rotkreuz, Switzerland)
using 5'nuclease real time PCR (TaqMan®) assay and fluo-
rescently labeled allele-specific probes. Following primers
and probes were used for GSTM1: forward 5'-GGA-
CATTTTGGAGAACCAGACC-3' and reverse 5'-CTGGATT-
GTAGCAGATCATGCC-3' primers and GSTM1-specific
probe 5'-VIC-TGGACAACCATATGCAG-MGB-3'; for
GSTT1: forward 5'-GTCATTCTGAAGGCCAAGGACTT-3'
and reverse 5'-GGCATCAGCTTCTGCTTTATGGT-3' prim-
ers and GSTT1-specific probe 5'-FAM-CACCTGCAGAC-
CCC-MGB-3'; for GSTP1  Ile105Val: forward 5'-
CCTGGTGGACATGGTGAATGAC-3' and reverse 5'-
CAGATGCTCACATAGTTGGTGTAGA-3' primers and
Ile105 -specific probe 5'-VIC-CTGCAAATACATCTCC-
MGB-3'and Val 105 -specific probe 5'-FAM-
CTGCAAATACGTCTCC-MGB-3'.  GSTM1/GSTT1  assays
were repeated for all DNA samples carrying double
homozygous GSTM1 and GSTT1 deletions using internal
positive GSTP1 controls. All double homozygous deletion
carriers could be confirmed. With this approach,
hemizygous GSTM1 or GSTT1 carriers were not distin-
guishable from homozygous carriers. In addition a 5%
random sample of all DNA samples was regenotyped with
highest reproducibility (>99.5%). Hardy-Weinberg equi-
librium (HWE) was tested for GSTP1 Ile105Val using Arle-
quin (Version 2.000) software [25].
Statistical analysis
The dependent variable, annual change in lung function,
was calculated by dividing the difference between follow-
up and baseline lung function by the number of follow-
up years. Multiple linear regression analysis was used to
estimate in a fixed effect model of the association of GST
Table 1: Baseline characteristics* of the included versus excluded SAPALDIA participants
Variables: Participants Included n = 4686 Participants Excluded† n = 4965
Women [N/%] 2455/52.4 2453/49.4
Age [years] 40.8 (± 11.5) 41.3 (± 11.8)
BMI at baseline [kg/m2] 23.7 (± 3.6) 24.2 (± 4.1)
Smoking
Non-smokers [N/%] 2325/49.6 1904/38.5
Former smokers [N/%] 948/20.2 1227/24.8
Current smokers [N/%] 1413/30.2 1819/36.7
Pack-years at baseline ‡ 18.4 (± 18.4) 19.6 (± 20.1)
Lung Function
FEV1 [L] 3.6 (± 0.8) 3.5 (± 0.9)
FEV1 % pred. § 100.2 (± 13.3) 98.0 (± 14.8)
FEV1/FVC 79.2 (± 7.6) 78.9 (± 8.4)
FEV1/FVC <70% 468/10.1 510/12.0
* expressed as mean (± SD) for quantitative variables and absolute numbers/percentages for categorical variable.
† SAPALDIA participants at the baseline examination who did not participate at follow-up (n = 3678) [21] or who were excluded from the present 
analysis due to missing information on outcome or covariate data (n = 1287).
‡ mean of pack-years among ever smoking subjects. Participants were defined as ever-smokers if they had smoked at least 20 packs of cigarettes or 
360 g of tobacco in their life.
§FEV1 % predicted calculations based on SAPALDIA specific prediction equations [55, 56].Respiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
Page 4 of 17
(page number not for citation purposes)
genotypes with annual change in lung function. Covari-
ates included in the models were baseline lung function,
age, sex, height, weight change during follow-up, study
center, level of education, exposure to gas and dust at
work at baseline, smoking status at baseline and at follow-
up, pack-years smoked at baseline and during follow-up.
Cumulative cigarette smoking exposure was summarized
in two separate variables: "pack-years smoked up to base-
line" and "pack-years smoked during follow-up". The fol-
lowing categories of smoking status were derived for the
current study: "Never smokers" reported to be non-smok-
ers at both surveys (n = 2258). "Ever smokers" had to have
smoked more than 20 packs of cigarettes or more than
360 g of tobacco (n = 2428) in their lifetime by the end of
the follow-up period. Ever smokers were further divided
into: "persistent smokers" reported current smoking at
both surveys (n = 1026), and "others" were all remaining
subjects, comprising participants reporting at both sur-
veys former smoking (n = 944), quitting smoking during
follow-up (n = 387), starting smoking during follow-up
(n = 38), non-smoking at baseline and former smoking at
follow-up (n = 29) and former smoking at baseline and
current smoking at follow-up (n = 4). 48 participants pro-
vided inconsistent smoking information. Exclusion of
these subjects in a sensitivity analysis did not change the
strength or the direction of the association observed.
Effect modification of genotype/lung function associa-
tions by gender, smoking status, and smoking intensity
(pack-years up to baseline and during follow-up in ever
smokers), as well as BHR and age, was assessed by includ-
ing according multiplicative interaction terms in the
regression models. Trend tests for the combination of
GSTT1 and GSTM1 genotypes were conducted by using a
genotype combination variable coded as "presence of
zero, one and two gene deletion polymorphisms" as ordi-
nal variable in the model. Two-sided p-values of <0.05
and <0.10 were considered as statistically significant for
main effects and interactions [26], respectively. Correc-
tion for multiple testing was done using the conservative
Bonferroni correction. The associations were corrected for
the number of statistical tests performed (main effects and
interactions with gender and smoking intensity) (thirty
comparisons per lung function parameter investigated,
consisting of fifteen tests in men and fifteen tests in
women: all; never smokers; persistent smokers). The Bon-
ferroni corrected significance level for the a priori hypoth-
eses regarding association between GST genotypes and
lung function change in men and women including the a
priori assessment of interaction with gender and smoking
and was P > 0.0017. Sensitivity analyses regarding age and
BHR were not corrected for multiple testing. All analyses
were conducted using STATA SE version 8.0 (Stata Corpo-
ration, TX, USA).
Results
Characteristics of the study population are summarized in
Table 2. The study included more women (52.4%) than
men (47.6%). Reflecting recruitment as a random sample
of the Swiss general population participants had on aver-
age good lung function at baseline and follow-up. FEV1
percent predicted at baseline and follow-up was 100.2%
and 97.0% of predicted values, respectively. The mean
annual change in FEV1 was -39.6 ml/yr (SD: ± 33.6) in
men and -31.8 ml/yr (± 26.2) in women, respectively.
Women were more likely to be never smokers. Among
smoking subjects, men smoked on average more heavily
than women (21.8 pack-years vs. 14.5 pack-years at base-
line; 7.1 vs. 5.5 pack-years during follow-up). The
observed GST genotype distributions agreed well with pre-
vious reports in Caucasians [19,27,28]. GSTM1  and
GSTT1 null genotypes were present in 53% and 18% of all
subjects. The homozygous GSTP1 Val/Val genotype was
present in 9.4% and its allele distribution was in Hardy-
Weinberg equilibrium.
INSERT [Table 2]
Association of GST genotypes with lung function decline
No independent association of GSTM1 or GSTP1 geno-
type with any of the lung function parameters was
observed, irrespective of gender. GSTT1  gene deletion
alone or in combination with GSTM1 deletion was asso-
ciated with accelerated lung function decline in men, but
not women. Men homozygous for the GSTT1 gene dele-
tion exhibited an excess annual change in FEV1 of -5.3 ml/
yr (P = 0.001). The GSTT1 effects on FVC and FEF25–75
were comparable in size and direction, but did not reach
statistical significance. Men carrying the double
homozygous gene deletions of GSTT1 and GSTM1 had on
average a -8.3 ml/yr greater annual decline in FEV1 than
men with at least one copy of both, the GSTT1 and the
GSTM1 gene (P for trend <0.001); the according excess
change was -6.5 ml/yr (P = 0.045) for FVC and -7.8 ml/yr
(P = 0.094) for FEF25–75. The interactions between gender
and GSTT1 deletion alone or in combination with GSTM1
deletion were statistically significant for FEV1, FEF25–75
and FVC (for GSTT1/GSTM1 combination only).
INSERT [Table 3]
The majority of the reported association results did not
withhold the conservative Bonferroni correction; however
the GSTT1 genotype alone or in combination with GSTM1
genotype showed a significant association with annual
change in FEV1 even after Bonferroni correction. The
effect of double homozygous GSTT1 and GSTM1 deletion
on lung function decline is graphically presented as pre-
dicted mean annual FEV1 decline in different genotype/
gender strata.Respiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
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INSERT [Figure 1]
Effect modification by smoking
An important determinant of premature lung function
decline is active smoking. In our study population, per-
sistent male smokers exhibited on average an -6.6 ml/yr
greater annual FEV1 change than never smoking men; the
average change in FEV1 was -42.8 ml/yr (± 35.6) in male
persistent smokers and -36.2 ml/yr (± 33.2) in male never
smokers. In persistent smokers each pack-year smoked
during follow-up was associated with an excess average
annual FEV1 change of -0.8 ml/yr. We assessed the impact
of genetic GST deficiency on lung function decline sepa-
rately for never smokers and persistent smokers; associa-
tions observed in ever-smokers were similar to those
reported here for persistent smokers (data not shown).
Irrespective of gender or smoking status no independent
effects of GSTM1 or GSTP1 Ile105Val genotype on accel-
erated decline of FEV1, FVC or FEF25–75 were observed.
Male persistent smokers with GSTT1 null genotype exhib-
ited on average an excess annual decline in FEV1 of -8.0
ml/yr (P = 0.013) when compared to persistent smokers
with  GSTT1  non-null genotype. The according GSTT1
effect in male never smokers was -5.6 ml/yr (P = 0.025).
The difference in GSTT1  effect between persistent and
never smokers was not statistically significant (P for inter-
Table 2: Characteristics* of the study population, the SAPALDIA Cohort
All Women Men
N 4686 2455/52.4% 2231/47.6%
Age [years] 40.8 (± 11.5) 41.2 (± 11.4) 40.4 (± 11.6)
BMI at baseline [kg/m2] 23.7 (± 3.6) 22.9 (± 3.8) 24.5 (± 3.2)
BMI at follow-up [kg/m2] 25.8 (± 4.4) 25.2 (± 4.8) 26.5 (± 3.8)
Weight change
during follow-up [kg] 5.6 (± 6.2) 5.5 (± 6.1) 5.7 (± 6.3)
Smoking †
Never smokers 2258/48.2 1354/55.2 904/40.5
Ever smokers 2428/51.8 1101/44.8 1327/59.5
Persistent smokers 1026/21.9 487/19.8 539/24.2
Others 1402/29.9 614/25.0 788/35.3
Pack-years up to baseline ‡ 18.4 (± 18.4) 14.5 (± 14.5) 21.8 (± 20.6)
Pack-years during follow-up ‡ 6.4 (± 8.5) 5.5 (± 6.5) 7.1 (± 9.8)
Lung Function
FEV1 at baseline [L] 3.6 (± 0.8) 3.1 (± 0.6) 4.1 (± 0.7)
FVC at baseline [L] 4.5 (± 1.1) 3.8 (± 0.6) 5.3 (± 0.8)
FEF25–75 at baseline [L] 3.4 (± 1.2) 3.1 (± 1.0) 3.8 (± 1.3)
Annual change FEV1 [ml/yr] -35.5 (± 30.2) -31.8 (± 26.2) -39.6 (± 33.6)
Annual change FVC [ml/yr] -24.2 (± 41.0) -20.6 (± 34.9) -28.3 (± 46.5)
Annual change FEF25–75 [ml/yr] -71.3 (± 65.4) -68.6 (± 59.4) -74.1 (± 71.2)
FEV1 % pred. at baseline § 100.2 (± 13.3) 100.8 (± 13.4) 99.4 (± 13.2)
FEV1 % pred. at follow-up § 97.0 (± 14.4) 98.6 (± 14.1) 95.4 (± 14.6)
FEV1/FVC at baseline [%] 79.2 (± 7.6) 80.4(± 7.4) 78.0 (± 7.7)
FEV1/FVC at follow-up [%] 74.8 (± 7.5) 75.5 (± 7.1) 74.0 (± 7.8)
FEV1/FVC at follow-up <70% 1030/22.0 473/19.3 557/25.0
Positive BHR at baseline [%] 612/16.1 394/20.3 218/11.7
Genotypes
GSTM1 deletion 2477/52.9 1306/53.2 11171/52.5
GSTT1 deletion 844/18.0 466/19.0 378/17.0
GSTP1 Ile105Val
Ile/Ile 2219/47.4 1162/47.3 1057/47.4
Ile/Val 2025/43.2 1068/43.5 957/42.9
Val/Val 442/9.4 225/9.2 217/9.7
* expressed as mean (± SD) for quantitative variables and absolute numbers/percentages for categorical variable.
† "Never" smokers reported non-smoking at both surveys. "Persistent" smokers reported current smoking at both surveys. "Others" comprised 
participants reporting at both surveys former smoking (n = 944), quitting smoking during follow-up (n = 387), starting smoking during follow-up (n 
= 38), non-smoking at baseline and former smoking at follow-up (n = 29) and former smoking at baseline and current smoking at follow-up (n = 4).
‡ mean of pack-years among ever smoking subjects. Ever-smokers encompass both, persistent smokers and others.
§FEV1 % predicted calculations based on predicted values from SAPALDIA specific prediction equations [55, 56].R
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Table 3: Adjusted* associations of GST genotypes† with excess annual decline in FEV1, FVC and FEF25–75 stratified by sex, the SAPALDIA Cohort.
Difference in mean annual change in lung function (ml/yr) ‡
FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
MEN
GSTT1 non-null 1853 --- --- 1806 --- --- 1787 --- ---
GSTT1 null 378 -5.3 -8.4, -2.1 0.001¶** 371 -5.2 -7.4, -1.3 0.17 366 -5.0 -11.7, 1.8 0.15
GSTM1 non-null 1060 --- --- 1040 --- --- 1030 --- ---
GSTM1 null 1171 -2.1 -4.5, 0.3 0.081 1137 -0.8 -4.0, 2.5 0.65 1123 -4.1 -9.2, 0.9 0.11
GSTP1 105 Ile/Ile 1057 --- --- 1037 --- --- 1025 --- ---
GSTP1 105 Ile/Val 957 0.09 -2.4, 2.6 0.94 929 -0.1 -3.5, 3.3 0.95 919 -2.7 -8.0, 2.6 0.32
GSTP1 105 Val/Val 217 -2.5 -6.6, 1.7 0.25 211 -3.2 -9.0, 2.5 0.27 209 -7.3 -16.1, 1.6 0.11
GSTM1T1 both non-null 885 --- --- 866 --- --- 860 --- ---
GSTM1T1 either null 1143 -1.8 -4.3, 0.7 --- 1114 0.9 -2.5, 4.4 --- 1097 -5.1 -10.5, 0.2 ---
GSTM1T1 both null 203 -8.3 -12.6, -3.9 <0.001¶** 197 -6.5 -12.5, -0.5 0.045¶ 196 -7.8 -17.0, 1.5 0.094
GSTT1*GSTM1Interaction 0.30 0.042¶ 0.55
WOMEN
GSTT1 non-null 1989 --- --- 1953 --- --- 1920 --- ---
GSTT1 null 466 -0.3 -2.5, 1.8 0.76 462 -1.6 -4.5, 1.3 0.28 455 3.4 -1.5, 8.3 0.18
GSTM1 non-null 1149 --- --- 1131 --- --- 1115 --- ---
GSTM1 null 1306 0.5 -1.2, 2.2 0.54 1284 1.1 -1.2, 3.4 0.36 1260 -0.8 -4.7, 3.1 0.69
GSTP1 105 Ile/Ile 1162 --- --- 1142 --- --- 1126 --- ---
GSTP1 105 Ile/Val 1068 -0.6 -2.4, 1.2 0.51 1050 0.6 -1.8, 3.0 0.64 1030 -3.0 -7.0, 1.1 0.15
GSTP1 105 Val/Val 225 -0.2 -3.3, 2.9 0.90 223 1.5 -2.6, 5.6 0.48 219 0.5 -6.5, 7.5 0.88
GSTM1T1 both non-null 931 --- --- 915 --- --- 902 --- ---
GSTM1T1 either null 1276 -0.9 -2.7, 1.0 --- 1254 -1.1 -3.5, 1.4 --- 1231 -0.6 -4.8, 3.5 ---
GSTM1T1 both null 248 1.6 -1.5, 4.6 0.24 246 1.3 -2.7, 5.4 0.42 242 3.2 -3.6, 10.0 0.53
GSTT1*GSTM1Interaction 0.026¶ 0.025¶ 0.66
Sex* Genotype Interaction††
sex*GSTT1 0.010¶ 0.56 0.043¶
sex*GSTM1 0.028¶ 0.23 0.19
sex*GSTP1 0.50 0.39 0.40
sex*GSTT1M1 <0.001¶ 0.015¶ 0.08¶
* The effects of GST genotypes are adjusted for the respective baseline lung function parameter, smoking status at baseline and follow-up, pack-years smoked at baseline and during follow-up, height, weight 
change between surveys, study area, gas and dust exposure at baseline and education level.
† GSTM1 and GSTT1 genotypes were dichotomized into absence vs. presence of homozygous gene deletions (non-null vs. null). The effect of the GSTP1 genotype on lung function change was investigated in 
a co-dominant genetic model with the Ile/Ile genotype as the reference group. The combined GSTM1 /GSTT1 genotype (GSTM1T1) was coded as "presence of zero, one and two homozygous gene deletion 
polymorphisms" and included as ordinal variable in the linear regression model.
‡ Change in lung function parameter represented the difference between lung function parameter measured at follow-up [ml] and the one measured at baseline [ml] divided by the duration of follow-up 
period [yr]. Coefficient values below zero correspond to an excess decline in lung function [ml/yr] compared to the decline in the reference group and coefficient values above zero correspond to a less 
steep decline in lung function compared of the reference group.
§Uncorrected P-values for differences between categories. Bonferroni corrected significance level for multiple comparisons: P < 0.0017.
¶Statisically significant (uncorrected P-value > 0.05). ** Statistically significant after Bonferoni-correction (P-value > 0.0017)
†† Interaction between genotype and gender was assessed by including interaction terms in the model.Respiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
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Predicted* mean annual change in lung function parameter by the combined GSTT1 and GSTM1 gene deletion genotype and  sex, the SAPALDIA cohort Figure 1
Predicted* mean annual change in lung function parameter by the combined GSTT1 and GSTM1 gene deletion genotype and 
sex, the SAPALDIA cohort. 
* adjusted for baseline FEV1, FVC and FEF25–75, respectively, as well as for smoking status at baseline and follow-up, pack-years 
smoked at baseline and during follow-up, height, weight change between surveys, study area, gas and dust exposure at baseline 
and education level. 
† P-values for difference with reference group GSTM1T1 both non-null.
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action>0.10). The GSTT1 effect in persistent smokers was
modified by packyears smoked to baseline (P for interac-
tion<0.001) and during follow-up (P for interaction =
0.029). Similar trends for the GSTT1 effect on FEV1
decline in smoking strata, though lacking statistical signif-
icance, were observed for FVC and less clearly for FEF25–75.
The  GSTT1  genotype alone or in combination with
GSTM1  genotype was not associated with excess lung
function change in women, irrespective of smoking status.
There was a suggestion that heterozygosity for the GSTP1
Ile105Val SNP was associated with slower decline in FVC
in persistent smokers (P = 0.030), but no according heter-
ozygous effects on FEV1 or FEF25–75  were observed.
INSERT [Table 4]
Sensitivity analysis: modification of the GST effects by 
BHR
The GST genotypes have previously been associated with
asthma and BHR [28]. Restriction of the analysis to sub-
jects without a report of asthma (data not shown) and
without the presence of BHR at either baseline or follow-
up (Table 5) revealed comparable associations in size
between GST genotypes and lung function change as
reported for the whole study population (Table 3), irre-
spective of gender and lung function parameter. Thus the
observed GST/lung function decline associations are not
merely due to an effect of GST on asthma or BHR.
BHR was previously shown to be predictive of COPD [29].
Results of the investigation of the GST effects on decline
in lung function among BHR positive subjects (Table 5)
suggested that the respective impact of GSTT1 and GSTM1
gene deletion might be modified by BHR. The interaction
between GST genotypes and BHR did not reach statistical
significance, though. In male BHR positive subjects,
GSTM1 rather then GSTT1 deficiency was associated with
accelerated decline in FEV1 (-8.2 ml/yr, P = 0.017) and
FEF25–75 (-12.4 ml/yr, P = 0.051). Again, the lung function
decline was strongest for the combined GSTM1/GSTT1
genotypes, consistent with a gene dose-response. For
both, FEV1 and FEF25–75 effect estimates for GSTM1T1
both null were stronger than those observed among male
BHR negative subjects. No association of GST genotype
with FVC was observed in male BHR positive subjects. In
BHR positive women again no statistically significant GST
genotype/lung function associations were observed.
INSERT [Table 5]
Sensitivity analysis: GST effect in age restricted 
subpopulation
Both, lung function growth and decline are age-depend-
ent processes. The SAPALDIA cohort also includes young
adults (age at baseline 18 to 60 years). To confirm that the
observed associations between GST genotype and lung
function change are due to an impact of these genotypes
on age-related decline, we restricted analysis to subjects
older than 30 years, an age at which lung growth has
ceased and age-related lung function decline started [30]
(data not presented). In men we observed associations of
GSTT1 alone or in combination with GSTM1 with change
in FEV1 and FVC that were similar in trend to the ones
observed in the entire study sample (for GSTT1 and FEV1:
-5.8 ml/yr (P = 0.001); for GSTM1 and GSTT1 both null
and FEV1: -7.4 ml/yr (P = 0.009)). The association with
change in FVC was more pronounced (for GSTT1: -4.4 ml/
yr (P = 0.08); for GSTM1 and GSTT1 both null: -9.5 ml/yr
(P = 0.005)). In contrast, the non-significant association
observed for GSTT1 genotype and change in FEF25–75 was
no longer present in men aged 30 years or older (for
GSTT1: -0.4 ml/yr (P = 0.89); for GSTM1 and GSTT1 both
null: -1.9 ml/yr (P = 0.72)). Instead, the association
between GSTM1 null genotype and excess annual change
in FEF25–75 became statistically significant (for GSTM1: -
7.6 ml/yr (P = 0.024)). In women over age 30 at baseline,
we did not observe any GST genotype/lung function
decline association.
Discussion
Our results suggest that genetic GSTT1 deficiency alone or
in combination with GSTM1 deficiency is independently
associated with an accelerated age-related decline of lung
function in men, but not women, irrespective of smoking
status. The impact size of the GSTT1 genotype was compa-
rable to the difference in FEV1 decline that we observed
between male persistent smokers and never smokers.
This is the first study reporting an association between
GST genotypes and lung function in the general adult
population. Genetically determined GST deficiency has
previously been associated with deficits in lung function
growth and respiratory symptoms in healthy and asth-
matic children exposed to oxidative inhalants such as high
ambient ozone concentrations and passive smoke, respec-
tively [20,31]. While GSTs are well known for their role in
the metabolism of exogenous toxic substrates including
tobacco derived substances, they also exhibit peroxidase
activity and thus might play an important role in oxidative
stress defense [15]. The fundamental relevance of the oxi-
dative stress pathway to respiratory health and disease is
evidenced by the fact that dietary and circulating antioxi-
dants have been suggested by a number of epidemiologi-
cal studies to protect the lung from accelerated pulmonary
function decline and other respiratory diseases [32-34].
The current observation that the GST genotype effects
were even present in never smokers living in study areas
with moderate concentrations of ambient ozone and
other air pollutants is in line with this notion and with
experimental data suggesting that various air pollutants asR
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) Table 4: Adjusted* associations of GST genotypes† with excess annual decline in FEV1, FVC and FEF25–75 stratified by smoking status and sex, the SAPALDIA Cohort.
MEN Difference in mean annual change in lung function (ml/yr) ‡
FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
Male Never Smokers n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
GSTT1 non-null 750 --- --- 731 --- --- 723 --- ---
GSTT1 null 154 -5.6 -10.6, -0.7 0.025¶ 150 -1.0 -7.8, 5.7 0.76 148 -8.5 -19.0, 1.9 0.11
GSTM1 non-null 432 --- --- 424 --- --- 420 --- ---
GSTM1 null 472 -2.4 -6.1, 1.4 0.22 457 -1.8 -6.8, 3.3 0.50 451 -4.4 -12.3, 3.5 0.27
GSTP1 105 Ile/Ile 433 --- --- 426 --- --- 420 --- ---
GSTP1 105 Ile/Val 389 -0.2 -4.2, 3.7 0.90 377 -0.1 -5.5, 5.2 0.96 375 -4.3 -12.5, 4.0 0.31
GSTP1 105 Val/Val 82 -2.0 -8.8, 4.7 0.56 78 -5.9 -15.1, 3.3 0.21 76 -4.5 -18.9, 9.9 0.54
GSTM1T1 both non-null 351 --- --- 344 --- --- 342 --- ---
GSTM1T1 either null 480 -2.2 -6.2, 1.7 --- 467 0.9 -4.4, 6.3 --- 459 -4.8 -13.1, 3.5 ---
GSTM1T1 both null 73 -9.7 -16.9, -2.5 0.029¶ 70 -7.1 -16.9, 2.7 0.26 70 -14.4 -29.6, 0.78 0.15
FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
Male Persistent Smokers n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
GSTT1 non-null 428 --- --- 417 --- --- 410 --- ---
GSTT1 null 111 -8.0 -14.2, -1.7 0.013¶ 109 -9.3 -17.6, -1.1 0.027¶ 106 -3.7 -16.9, 9.5 0.58
GSTM1 non-null 256 --- --- 249 --- --- 244 --- ---
GSTM1 null 283 -4.2 -9.3, 1.0 0.11 277 -4.1 -10.8, 2.7 0.24 272 -6.1 -16.9, 4.7 0.27
GSTP1 105 Ile/Ile 258 --- --- 252 --- --- 246 --- ---
GSTP1 105 Ile/Val 228 0.2 -5.3, 5.6 0.95 222 -4.6 -11.7, 2.5 0.20 218 4.7 -6.6, 16.0 0.41
GSTP1 105 Val/Val 53 -1.0 -10.0, 7.9 0.82 52 -1.0 -12.7, 10.7 0.87 52 -4.7 -23.1, 13.7 0.62
GSTM1T1 both non-null 207 --- --- 200 --- --- 197 --- ---
GSTM1T1 either null 270 -4.9 -10.4, 0.5 --- 266 -6.6 -13.8, 0.6 --- 260 -5.8 -17.3, 5.7 ---
GSTM1T1 both null 62 -11.5 -20.1, -2.9 0.022¶ 60 -11.5 -22.8, -0.2 0.072 59 -9.3 -27.3, 8.8 0.48
Genotype*Packyears Interaction ††
GSTT1*during follow-up 0.029¶ 0.67 0.89
GSTT1*up to baseline 0.001¶ 0.02¶ 0.41
GSTM1*during follow-up 0.50 0.30 0.33
GSTM1*up to baseline 0.39 0.70 0.83
GSTP1*during follow-up 0.96 0.37 0.65
GSTP1*up to baseline 0.31 0.84 0.32
GSTM1T1*during follow-up 0.75 0.11 0.40
GSTM1T1*up to baseline 0.31 0.34 0.88
WOMEN Difference in mean annual change in lung function (ml/yr) ‡
FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
Female Never Smokers n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
GSTT1 non-null 1091 --- --- 1072 --- --- 1053 --- ---
GSTT1 null 263 -0.7 -3.6, 2.3 0.66 260 -1.7 -5.7, 2.3 0.40 256 0.5 -6.2, 7.2 0.88R
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GSTM1 non-null 629 --- --- 617 --- --- 607 --- ---
GSTM1 null 725 0.5 -1.8, 2.8 0.67 715 0.9 -2.2, 4.1 0.56 702 -0.7 -6.0, 4.6 0.79
GSTP1105Ile/Ile 644 --- --- 631 --- --- 621 --- ---
GSTP1105Ile/Val 582 -1.2 -3.6, 1.2 0.32 575 -1.4 -4.7, 1.9 0.41 564 -2.5 -8.0, 3.1 0.38
GSTP1105Val/Val 128 -0.8 -4.9, 3.3 0.69 126 0.3 -5.3, 5.9 0.91 124 1.0 -8.5, 10.4 0.84
GSTM1T1 both non-null 506 --- --- 496 --- --- 488 --- ---
GSTM1T1 either null 708 -1.5 -3.9, 1.0 --- 697 -0.6 -4.0, 2.7 --- 684 -3.8 -9.5, 1.9 ---
GSTM1T1 both null 140 1.8 -2.3, 5.9 0.20 139 0.44 -5.1, 6.0 0.89 137 3.3 -5.9, 12.6 0.19
FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
Female Persistent Smokers n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
GSTT1 non-null 428 --- --- 385 --- --- 376 --- ---
GSTT1 null 111 4.8 -0.3, 9.8 0.065 92 3.5 -3.1, 10.2 0.30 92 12.7 1.7, 23.6 0.029¶
GSTM1 non-null 256 --- --- 230 --- --- 227 --- ---
GSTM1 null 283 1.2 -2.9, 5.2 0.57 247 1.8 -3.6, 7.1 0.51 241 -0.5 -9.4, 8.3 0.91
GSTP1 105 Ile/Ile 258 --- --- 227 --- --- 223 --- ---
GSTP1 105 Ile/Val 228 1.9 -2.3, 6.0 0.38 214 6.0 0.6, 11.5 0.03¶ 210 -2.1 -11.1, 7.0 0.66
GSTP1 105 Val/Val 53 4.3 -3.4, 12.1 0.27 36 3.0 -7.2, 13.3 0.56 35 10.5 -6.5, 27.5 0.23
GSTM1T1 both non-null 207 --- --- 194 --- --- 191 --- ---
GSTM1T1 either null 270 3.2 -1.1, 7.4 --- 227 1.5 -4.1, 7.2 --- 221 5.8 -3.6, 15.1 ---
GSTM1T1 both null 62 4.0 -2.7, 10.7 0.27 56 5.3 -3.5, 14.1 0.50 56 7.4 -7.1, 21.8 0.40
Genotype*Packyears Interaction †† Persistent Persistent Persistent
GSTT1*during follow-up 0.23 0.75 0.09¶
GSTT1*up to baseline 0.20 0.52 0.19
GSTM1*during follow-up 0.79 0.58 0.44
GSTM1*up to baseline 0.69 0.72 0.58
GSTP1*during follow-up 0.33 0.065 0.50
GSTP1*up to baseline 0.80 0.41 0.44
GSTM1T1*during follow-up 0.67 0.82 0.81
GSTM1T1*up to baseline 0.68 0.88 0.82
* The effects of GST genotypes are adjusted for the respective baseline lung function parameter, smoking status at baseline and follow-up, pack-years smoked at baseline and during follow-up, height, weight 
change between surveys, study area, gas and dust exposure at baseline and education level.
† GSTM1 and GSTT1 genotypes were dichotomized into absence vs. presence of homozygous gene deletions (non-null vs. null). The effect of the GSTP1 genotype on lung function change was investigated in 
a co-dominant genetic model with the Ile/Ile genotype as the reference group. The combined GSTM1 /GSTT1 genotype (GSTM1T1) was coded as "presence of zero, one and two homozygous gene deletion 
polymorphisms" and included as ordinal variable in the linear regression model.
‡ Change in lung function parameter represented the difference between lung function parameter measured at follow-up [ml] and the one measured at baseline [ml] divided by the duration of follow-up 
period [yr]. Coefficient values below zero correspond to an excess decline in lung function [ml/yr] compared to the decline in the reference group and coefficient values above zero correspond to a less 
steep decline in lung function compared of the reference group.
§Uncorrected P-values for differences between categories. Bonferroni corrected significance level for multiple comparisons: P < 0.0017. 
ll Interaction between pack-years and genotype in smokers was assessed by including interaction terms in the models. Cumulative cigarette smoking exposure was summarized in two separate variables: 
"pack-years smoked up to baseline" and "pack-years smoked during follow-up".
¶Statisically significant (uncorrected P-value > 0.05).
Table 4: Adjusted* associations of GST genotypes† with excess annual decline in FEV1, FVC and FEF25–75 stratified by smoking status and sex, the SAPALDIA Cohort. (Continued)Respiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
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Table 5: Adjusted* associations of GST genotypes† with excess annual decline in FEV1, FVC and FEF25–75 in men and women, stratified 
by absence or presence of BHR at baseline or follow-up, the SAPALDIA Cohort.
BHR Difference in mean annual change in lung function (ml/yr) ‡
negative FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
MEN
GSTT1 non-null 965 --- --- 948 --- --- 941 --- ---
GSTT1 null 209 -4.4 -8.3, -0.5 0.027¶ 208 -3.8 -9.0, 1.3 0.14 207 -4.2 -13.2, 4.8 0.36
GSTM1 non-null 560 --- --- 550 --- --- 546 --- ---
GSTM1 null 614 -0.8 -3.8, 2.2 0.58 606 0.2 -3.7, 4.2 0.91 602 -3.4 -10.4, 3.5 0.33
GSTP1 105 Ile/Ile 557 --- --- 547 --- --- 542 --- ---
GSTP1 105 Ile/Val 511 0.9 -4.1, 2.2 0.56 505 -0.7 -4.9, 3.4 0.95 503 -4.3 -11.6, 2.9 0.24
GSTP1 105 Val/Val 106 -0.6 -6.0, 4.9 0.84 104 -0.7 -7.9, 6.6 0.86 103 -3.7 -16.3, 9.0 0.57
GSTM1T1 both non-null 460 --- --- 450 --- --- 447 --- ---
GSTM1T1 either null 605 -0.5 -3.7, 2.7 --- 598 0.7 -3.5, 4.9 --- 593 -3.2 -10.5, 4.1 ---
GSTM1T1 both null 109 -6.4 -11.8, -1.0 0.062 108 -5.1 -12.3, 2.1 0.27 108 -8.0 -20.5, 4.5 0.41
FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
WOMEN
GSTT1 non-null 812 --- --- 808 --- --- 803 --- ---
GSTT1 null 181 1.2 -1.8, 4.1 0.43 181 0.3 -3.9, 4.5 0.88 180 5.4 -2.0, 12.9 0.15
GSTM1 non-null 459 --- --- 458 --- --- 456 --- ---
GSTM1 null 534 0.7 -1.6, 3.0 0.55 531 0.2 -3.0, 3.5 0.88 527 2.1 -3.7, 7.8 0.48
GSTP1 105 Ile/Ile 472 --- --- 470 --- --- 469 --- ---
GSTP1 105 Ile/Val 430 -0.6 -2.4, 1.2 0.51 428 0.5 -2.9, 3.9 0.76 425 -5.6 -11.6, 0.5 0.072
GSTP1 105 Val/Val 91 -0.2 -3.3, 2.9 0.90 91 4.3 -1.6, 10.2 0.15 89 -3.6 -14.1, 6.9 0.50
GSTM1T1 both non-null 373 --- --- 372 --- --- 370 --- ---
GSTM1T1 either null 525 -1.5 -3.9, 0.9 --- 522 -1.1 -4.6, 2.3 --- 519 4.4 -1.7, 10.6 ---
GSTM1T1 both null 95 0.1 -4.1, 4.3 0.24 95 2.3 -3.6, 8.1 0.46 94 5.5 -5.0, 15.9 0.31
BHR Difference in mean annual change in lung function (ml/yr) ‡
positive FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
MEN
GSTT1 non-null 276 --- --- 267 --- --- 265 --- ---
GSTT1 null 51 -5.5 -14.7, 3.8 0.24 50 -5.5 -17.3, 6.3 0.36 50 -7.0 -24.2, 
10.2
0.42
GSTM1 non-null 165 --- --- 161 --- --- 161 --- ---
GSTM1 null 162 -8.2 -14.9, -1.5 0.017¶ 156 -2.8 -11.4, 5.8 0.53 154 -12.4 -24.9, 
0.08
0.051
GSTP1 105 Ile/Ile 142 --- --- 139 --- --- 137 --- ---
GSTP1 105 Ile/Val 146 -0.7 -8.0, 6.6 0.84 139 -6.0 -15.3, 3.3 0.20 139 7.8 -5.8, 21.4 0.26
GSTP1 105 Val/Val 39 0.07 -10.8, 
10.9
0.99 39 -2.8 -16.4, 
10.9
0.69 39 -2.9 -22.8, 
17.0
0.77
GSTM1T1 both non-null 139 --- --- 136 --- --- 136 --- ---
GSTM1T1 either null 163 -6.1 -13.2, 1.0 --- 156 -0.2 -9.3, 8.8 --- 154 -11.6 -24.8, 1.6 ---
GSTM1T1 both null 25 -17.3 -30.6, .4,1 0.024¶ 25 -13.4 -30.2, 3.4 0.27 25 -20.2 -44.6, 4.3 0.12
Among men: 
interaction 
Genotype* BHR ††Respiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
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GSTT1*BHR 0.71 0.89 0.65
GSTM1*BHR 0.33 0.94 0.66
GSTP1*BHR 0.44 0.84 0.24
GSTM1T1*BHR 0.57 0.99 0.81
FEV1 (ml/yr) FVC (ml/yr) FEF25–75 (ml/yr)
n Coeff. 95%CI p-value § n Coeff. 95%CI p-value § n Coeff. 95%CI p-value §
WOMEN
GSTT1 non-null 437 --- --- 428 --- --- 423 --- ---
GSTT1 null 101 -0.8 -5.8, 4.3 0.77 100 -1.1 -7.6, 5.4 0.74 99 0.8 -9.2, 10.9 0.87
GSTM1 non-null 251 --- --- 246 --- --- 244 --- ---
GSTM1 null 287 0.6 -3.4, 4.6 0.76 282 1.0 -4.2, 6.1 0.72 278 0.9 -7.1, 8.8 0.83
GSTP1 105 Ile/Ile 250 --- --- 246 --- --- 243 --- ---
GSTP1 105 Ile/Val 250 -2.4 -6.6, 1.7 0.24 244 -1.8 -7.1, 3.4 0.50 242 -5.5 -13.7, 2.7 0.19
GSTP1 105 Val/Val 38 2.2 -5.8, 10.2 0.59 38 5.3 -4.9, 15.6 0.31 37 -6.3 -22.2, 9.6 0.43
GSTM1T1 both non-null 206 --- --- 202 --- --- 200 --- ---
GSTM1T1 either null 276 -1.5 -7.8, 2.8 --- 270 -1.5 -7.0, 3.9 --- 267 -2.8 -11.3, 5.7 ---
GSTM1T1 both null 56 1.9 -5.0, 8.8 0.56 56 2 -6.8, 10.8 0.68 55 5.4 -8.4, 19.1 0.46
Among women: 
interaction 
Genotype* BHR ††
GSTT1*BHR 0.25 0.23 0.52
GSTM1*BHR 0.85 0.67 0.47
GSTP1*BHR 0.77 0.87 0.35
GSTM1T1*BHR 0.41 0.85 0.24
* The effects of GST genotypes are adjusted for the respective baseline lung function parameter, smoking status at baseline and follow-up, pack-
years smoked at baseline and during follow-up, height, weight change between surveys, study area, gas and dust exposure at baseline and education 
level.
† GSTM1 and GSTT1 genotypes were dichotomized into absence vs. presence of homozygous gene deletions (non-null vs. null). The effect of the 
GSTP1 genotype on lung function change was investigated in a co-dominant genetic model with the Ile/Ile genotype as the reference group. The 
combined GSTM1 /GSTT1 genotype (GSTM1T1) was coded as "presence of zero, one and two homozygous gene deletion polymorphisms" and 
included as ordinal variable in the linear regression model.
‡ Change in lung function parameter represented the difference between lung function parameter measured at follow-up [ml] and the one 
measured at baseline [ml] divided by the duration of follow-up period [yr]. Coefficient values below zero correspond to an excess decline in lung 
function [ml/yr] compared to the decline in the reference group and coefficient values above zero correspond to a less steep decline in lung 
function compared of the reference group.
§Uncorrected P-values for differences between categories.
¶Statistically significant (uncorrected P-value > 0.05).
†† Interaction between genotype and BHR was assessed by including interaction terms in the model.
Table 5: Adjusted* associations of GST genotypes† with excess annual decline in FEV1, FVC and FEF25–75 in men and women, stratified 
by absence or presence of BHR at baseline or follow-up, the SAPALDIA Cohort. (Continued)Respiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
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well as chronic inflammatory processes can cause oxida-
tive damage to the lung tissue at low levels [35].
The GSTT1 effect was most consistent for FEV1 and overall
comparable in direction for FVC and FEF25–75 in our study.
Yet our results suggest that the respective impacts of GST
genotypes on the different lung function parameters may
depend on the smoking status, BHR and age. The strength
of the GSTT1 association with FVC and FEF25–75 differed
between never smokers and persistent smokers. The effect
on change in FEF25–75 was not observed in persistent
smokers as also reflected by the lack of interaction of
smoking history (pack-years) with GSTT1 genotype, sug-
gesting that the GSTT1 affects predominately large airway
caliber in smokers. In addition no statistically significant
GSTT1  effect on any lung function parameter was
observed in subjects with bronchial hyperresponsiveness.
Accelerated decline in FEV1 has been well characterized to
correlate with development of COPD [36], but measures
of small airways function such as changes in FEF25–75 have
also been reported to be of relevance in COPD [37]. Air
pollutant exposure to ozone [38] and NO2 [39] has often
been associated with a greater decline in FEF25–75 than in
FEV1. Differences in age, as well as differences in geno-
types investigated between our participants and previous
study populations may explain in part the inconsistency
in the GST effects on various lung function parameters.
Alterations in FEF25–75 and FEF25–75/FVC have been inter-
preted as indicators of airway-parenchymal dysanaptic
lung growth. These parameters may be of greater relevance
as an outcome for GST and oxidant effects during child-
hood. Ongoing research into genetic determinants of var-
ious lung function parameters may provide further insight
into the biology of different lung function parameters
[40].
A novel finding of our population-based study is the pro-
nounced gender difference in the association between
GST genotypes and age-related change in lung function.
Though the biological basis of these observed gender dif-
ferences is unknown, gender differences in lung function
and respiratory diseases have consistently been observed
throughout life. They can be attributed in part to sex-spe-
cific immunological and hormonal patterns associated
with lung function [41]. In addition, men and women
seem to differ in susceptibility to exogenous exposures.
On one hand comparative studies suggest that women
recover better than men from the adverse effects of
tobacco smoke [42-44]. On the other hand there is evi-
dence that women had greater respiratory deficits per
pack-year smoked [45] as well as higher DNA adducts lev-
els when adjusted for cigarette dose [46]. Several other
lines of evidence indicate in contrast that women might
be more resistant to oxidative stress than men. In smokers,
air flow obstruction was reported to be more strongly
associated with the presence of high-grade preinvasive
epithelial lesion in men than in women [47]. Women
compared to men were found to exhibit increased sys-
temic antioxidant capacities such as higher glutathione
blood levels [48], increased glutathione peroxidase activ-
ity [49] and less oxidant-damaged DNA at advanced age
[50,51]. In addition, women often report increased anti-
oxidant intake when compared to men, which may make
them less receptive for an effect of low penetrance gene
variants [34]. Finally, recently reported evidence suggests
that the estrogen receptor is involved in the up-regulation
of oxidative stress defensive genes including GSTP1 [52]
supporting the notion that sex-specific mechanisms in the
defense response to oxidative stress exist. If confirmed by
additional studies, our results which point to a sex-spe-
cific GST impact on lung function might be indicative of a
broad biological basis for gender difference in susceptibil-
ity to airborne toxicants.
We observed in the male SAPALDIA population differ-
ences in the relative impact of specific GST polymor-
phisms on lung function. In fact, results from previous
studies suggest that the respective relevance of GST genes
on respiratory health may depend on age, health and
exposure status of the study population [16,18,19,53,54].
The GSTT1 gene deletion polymorphism has previously
been identified as an important determinant of age-
related lung function change [19,53]. In the Lung Health
Study (LHS) the rate of lung function decline was acceler-
ated in GSTT1  deficient smokers with mild COPD
[19,53]. No gender difference was observed, but women
were underrepresented in the LHS. The GSTT1 effect was
stronger in mild as opposed to heavy smokers, whereas in
our study the GSTT1  effect was more pronounced in
smokers and with increasing pack-years. This discrepancy
to the LHS results might be attributable to the compara-
tively better respiratory health state of the SAPALADIA
participants (FEV1 % pred. [55,56] at follow-up: 97%)
and to their more moderate smoking habits. The relative
impact of specific GST genotypes on lung function in chil-
dren may be different from that in adults. Gilliland et al.
[20] reported lower lung function growth in children with
GSTP1 105Val and GSTM1 null genotypes, but not with
GSTT1 null genotype. In agreement with our results, no
independent GSTM1 effect on pulmonary function was
observed in healthy, non-smoking freshmen students,
irrespective of their antioxidant intake [34]. Exclusion of
younger age groups in our study population did not mod-
ify the reported associations, demonstrating that the find-
ings on association between GST genotypes and lung
function change were mostly due to the genotype impact
on age related lung function decline rather than on lung
function growth. As suggested by our sensitivity analysis
the relative impact of GSTT1 or GSTM1 gene deletion may
also depend on the presence or absence of BHR. There isRespiratory Research 2007, 8:2 http://respiratory-research.com/content/8/1/2
Page 14 of 17
(page number not for citation purposes)
evidence that BHR responsive airways are more vulnera-
ble to oxidative particles and to airway inflammation in
general [57]. This altered physiology of the BHR positive
lung tissue might provide a pathophysiologic basis for the
respective impact of GSTM1 deficiency reported here.
Results are most inconsistent with regard to the GSTP1
Ile105Val genotype. The GSTP1 105Val allele was found
to be protective against asthma and BHR [54]. In the LHS
study  GSTP1  105Val/Val genotype was associated with
lower lung function at baseline as well as with more rapid
lung function decline in smokers with high baseline lung
function values [19]. Yet the combination of GSTM1 and
GSTT1 gene deletion and GSTP1 105Ile/Ile was defined as
risk genotype in the follow-up study of the LHS [53]. In
other studies, the GSTP1 105Ile/Ile genotype was incon-
sistently associated with COPD [13,54,58]. In vitro assays
further underline the complexity of the functional impact
of the GSTP1 Ile105Val polymorphism, since the relative
activity of the variants is substrate dependent [59]. GSTP1,
the most abundantly expressed member of the GST gene
family in the lung [60], may have a complex impact on
respiratory disease. GSTP1 appears to act not only as a
detoxifying and antioxidative enzyme, but also as direct
inhibitor of the C-Jun N terminal kinase [61]. Accord-
ingly, low GSTP1 expression or activity has been reported
to promote apoptosis in lung epithelium [54,62]. Future
studies investigating more comprehensively genetic varia-
tion and haplotypes of the GSTP1 gene should improve
our understanding of the role of GSTP1 at various devel-
opmental and phenotypic levels of respiratory health.
The strength of the SAPALDIA cohort is its prospective
design, its large sample size as well as the detailed charac-
terization of study participants. However, several limita-
tions of the study deserve to be discussed. First, the study
cohort was evaluated at two single time points eleven
years apart and the range of factors influencing lung func-
tion decline were assessed through personal interviews
depending on reporting/recalling bias of the study partic-
ipants. Also there is the concern for selection bias for par-
ticipation at follow-up. Comparison of baseline
characteristics of SAPALDIA participants included in this
investigation with SAPALDIA cohort participants not
included in this analysis due to missing covariate infor-
mation suggested that the population sample investigated
here represents a younger, and less actively smoking and
healthier sample. GST genotypes were not associated with
age or smoking behavior among subjects included in this
study. Since it is not likely that GST genotypes influenced
study participation, non-participation at baseline, loss to
follow-up and exclusion of participants due to lacking
covariate information is unlikely to invalidate the results
presented. Second, a hypothetical limitation of our asso-
ciation study may be potential population stratification
since the Swiss population consists of multiple language
groups. Deviation of HWE of the GSTP1 Ile105Val geno-
type was not observed within the three language groups
presented in our study (French, German and Italian); the
genotype distribution was comparable in the three lan-
guage groups. The prevalence of gene deletion genotypes
of GSTM1 and GSTT1 and were not statistically signifi-
cantly different by language region or nationality. Neither
language group nor Swiss nationality did modify the
observed associations between GST deficient genotypes
and lung function decline. Given the low power of HWE
[63], genotype data from additional unlinked genetic
markers should ideally be used for testing population
admixture [64]. However limited funding prohibited this
control of population stratification in our study. Never-
theless we do not expect population stratification in this
Swiss cohort to invalidate the observed associations since
genetic homogeneity of Caucasian Western-Central Euro-
pean populations [65] has been repeatedly described. A
further limitation of the study is the fact that the genetic
analysis chosen does not permit to disentangle heterozy-
gotes from homozygotes wild type GSTT1 or GSTM1 gen-
otypes. It is conceivable that even stronger associations
with lung function could have been observed in a contrast
of subjects without any deletion allele versus no GSTT1
and GSTM1 gene. Finally sample size was limited for the
assessment of GST genotype effects among BHR positive
subjects.
In conclusion our results suggest that common genetic
polymorphisms can influence the rate of lung function
decline in the general population. A large proportion of
the Caucasian population carry one or both GST gene
deletions (~20% of GSTT1  gene deletion, ~50% the
GSTM1 gene deletion and ~10% of GSTT1/GSTM1 gene
deletion carriers). The high prevalence and the strong
effect size, which is comparable to the effect of smoking,
underscore the public health relevance of our results.
Additional studies need to confirm and identify the bio-
logical mechanisms underlying the newly observed gen-
der difference in GST genotype effects on age-related lung
function decline.
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